Xjow

Description

XJow is identified by the SPL Code 34089-3. Further details regarding its chemical composition, molecular weight, dosage form, and inactive ingredients are not provided in the extracted data.

Uses and Indications

This drug is indicated for the temporary relief of minor aches and pains associated with sore muscles and joints. Specifically, it is effective for conditions such as arthritis, simple backache, bruises, cramps, and muscle strains and sprains.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

For adults and children aged 12 years and older, the recommended dosage involves applying the gel to the affected area. The healthcare professional should instruct the patient to massage the dispensed gel into the affected area until it is thoroughly absorbed. This application may be performed as necessary, but it is important not to exceed four applications per day.

For children under 12 years of age, it is advised to consult a physician prior to use to determine the appropriate dosage and administration guidelines.

Contraindications

Use is contraindicated in children due to the risk of accidental ingestion. In the event of accidental ingestion, it is imperative to seek medical assistance or contact a Poison Control Center immediately.

Warnings and Precautions

For external use only, this product must be utilized strictly as directed. Healthcare professionals should advise patients against tightly bandaging the area of application or using it in conjunction with heating pads. It is imperative to avoid contact with the eyes and mucous membranes, and the product should not be applied to wounds or damaged skin. Additionally, it is contraindicated to use this product alongside other ointments, creams, sprays, or liniments. Application to irritated skin or in cases where excessive irritation develops is also not recommended. Patients should be instructed to wash their hands thoroughly with cool water after use to prevent unintended exposure.

Patients should be advised to discontinue use and consult a healthcare professional if any of the following occur: the condition worsens, symptoms persist for more than 7 days, symptoms clear up and then reoccur within a few days, redness is present, or irritation develops.

For individuals who are pregnant or breastfeeding, it is essential to seek guidance from a healthcare professional prior to use.

In the event of accidental ingestion, immediate medical assistance should be sought, or the patient should contact a Poison Control Center without delay.

Side Effects

Patients should be aware that this product is for external use only. It is essential to use the product strictly as directed and to avoid bandaging tightly or using it in conjunction with a heating pad. Contact with the eyes or mucous membranes should be avoided, and the product must not be applied to wounds or damaged skin. Additionally, it should not be used with other ointments, creams, sprays, or liniments, nor should it be applied to irritated skin or if excessive irritation develops. Patients are advised to wash their hands with cool water after use.

In the event that the condition worsens, symptoms persist for more than 7 days, or if symptoms clear up and then reoccur within a few days, patients should stop use and consult a doctor. The presence of redness or the development of irritation also warrants discontinuation of use and seeking medical advice.

For pregnant or breastfeeding individuals, it is recommended to consult a health professional before using this product.

Drug Interactions

Co-administration of this medication with other topical formulations, including ointments, creams, sprays, or liniments, is contraindicated. The use of multiple topical agents may lead to altered absorption or efficacy of the treatment, potentially resulting in adverse effects or diminished therapeutic outcomes.

There are no specific interactions identified with laboratory tests associated with this medication. Therefore, routine monitoring of laboratory parameters is not required in the context of drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Xjow (menthol). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should consult a physician prior to use. For adolescents and children aged 12 years and older, the recommended application involves massaging the dispensed gel into the affected area until thoroughly absorbed. This can be done as necessary, but the application should not exceed four times a day.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered, as the effects on fetal outcomes and breastfeeding infants are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider the potential risks associated with excessive administration of the medication.

It is essential to monitor patients closely for any signs or symptoms that may arise from an overdose. Symptoms may vary depending on the medication's pharmacological profile and the individual patient's response.

In the event of suspected overdosage, immediate medical intervention is recommended. Healthcare providers should initiate supportive care and symptomatic treatment as necessary. It is advisable to consult local poison control centers or relevant medical authorities for guidance on management protocols specific to the medication in question.

Documentation of the incident, including the amount ingested and the time of exposure, is crucial for effective management and treatment planning. Continuous monitoring of the patient's vital signs and clinical status is imperative until they are stabilized.

Overall, while specific overdosage information is not available, vigilance and prompt action are key components in managing potential overdose situations effectively.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children. It is important to emphasize that if the medication is accidentally ingested, patients should seek medical help or contact a Poison Control Center immediately. This precaution is vital to ensure the safety and well-being of children.

Storage and Handling

The product is supplied in a configuration that ensures optimal preservation of its integrity. It is essential to store the product in a cool, dry place, ensuring that the lid is closed tightly to prevent contamination and maintain efficacy. Proper storage conditions are critical for the product's stability and longevity.

Additional Clinical Information

The medication is administered topically, with specific instructions for different age groups. Adults and children aged 12 years and older should apply the gel to the affected area, massaging it in until fully absorbed, and may use it as necessary, not exceeding four applications per day. For children under 12 years of age, consultation with a physician is recommended prior to use.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Xjow, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)